{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:09:26Z","timestamp":1794215366781,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["312396\/2021\u20130"],"award-info":[{"award-number":["312396\/2021\u20130"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["552120\/2011\u20131"],"award-info":[{"award-number":["552120\/2011\u20131"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/10052\u20131"],"award-info":[{"award-number":["2018\/10052\u20131"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2020\/03419\u20136"],"award-info":[{"award-number":["2020\/03419\u20136"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.tice.2022.101988","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:23:12Z","timestamp":1670257392000},"page":"101988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["New synthetic nano-immunotherapy (OncoTherad\u00ae) for non-muscle invasive bladder cancer: Its synthesis, characterization and anticancer property"],"prefix":"10.1016","volume":"80","author":[{"given":"W.J.","family":"F\u00e1varo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.C.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.R.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.B.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Deckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.C.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2022.101988_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1475-2867-11-33","article-title":"IFN-\u03b3, IL-17 and TGF-\u03b2 involvement in shaping the tumor microenvironment: the significance of modulating such cytokines in treating malignant solid tumors","volume":"11","author":"Alshaker","year":"2011","journal-title":"Cancer Cell Int"},{"issue":"15","key":"10.1016\/j.tice.2022.101988_bib2","article-title":"Oncotherad immunotherapy elicits promising responses in Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer: Results from phase I\/ II study","volume":"38","author":"Alonso","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2022.101988_bib3","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/1953\/1\/012012","article-title":"Safety and efficacy of oncotherad nano-immunotherapy in patients with non-muscle invasive bladder cancer","volume":"1953","author":"Alonso","year":"2021","journal-title":"J. Phys. Conf. Ser."},{"issue":"7-Supl.","key":"10.1016\/j.tice.2022.101988_bib4","article-title":"Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tice.2022.101988_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2022.101988_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.03.001","article-title":"Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists","volume":"154","author":"Bourquin","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.tice.2022.101988_bib7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.tice.2022.101988_bib8","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/1323\/1\/012018","article-title":"OncoTherad: A new nanobiological response modifier, its toxicological and anticancer activities","volume":"1323","author":"Dur\u00e1n","year":"2019","journal-title":"J. Phys. Conf. Ser."},{"issue":"12","key":"10.1016\/j.tice.2022.101988_bib9","article-title":"The World Health Organization\/ International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder","volume":"22","author":"Epstein","year":"1998","journal-title":"Bladder Consens. Conf. Comm. Am. J. Surg. Pathol."},{"key":"10.1016\/j.tice.2022.101988_bib10","unstructured":"F\u00e1varo, W., Dur\u00e1n-Caballero, N.E., 2017, Process of obtaining a nanostructured complex (CFI-1), associated to nanostructured CFI-1 with a protein (MRB-CFI-1) and its use. Brazil Patent No. PIBR10.2017.012768.0."},{"issue":"15 suppl.","key":"10.1016\/j.tice.2022.101988_bib11","article-title":"Single-arm phase I\/II study of the safety and efficacy of OncoTherad immunomodulator in patients BCG-refractory or relapsed non-muscle invasive bladder cancer","volume":"37","author":"F\u00e1varo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"15 suppl.","key":"10.1016\/j.tice.2022.101988_bib12","article-title":"Role of OncoTherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK\/RANKL signaling: New therapeutic perspective for non-muscle invasive bladder cancer","volume":"37","author":"F\u00e1varo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tice.2022.101988_bib13","first-page":"27","article-title":"Effects of P-MAPA as immunomodulator on markers for energy metabolism in bladder cancer. Ann","volume":"3","author":"F\u00e1varo","year":"2020","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.tice.2022.101988_bib14","first-page":"2020","article-title":"A method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use","volume":"493","author":"F\u00e1varo","year":"2020","journal-title":"US Pat. Appl."},{"key":"10.1016\/j.tice.2022.101988_bib15","unstructured":"F\u00e1varo, W.J., Dur\u00e1n-Caballero, N.E., 2021a, Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use. USPatent 20210238044-A1."},{"key":"10.1016\/j.tice.2022.101988_bib16","unstructured":"F\u00e1varo, W.J., Dur\u00e1n-Caballero, N.E., 2021b, Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use. USPatent.20210238045-A1."},{"key":"10.1016\/j.tice.2022.101988_bib17","unstructured":"F\u00e1varo, W.J., Dur\u00e1n-Caballero, N.E., 2021c, Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use. USPatent. 20210238046-A1."},{"key":"10.1016\/j.tice.2022.101988_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12032-021-01612-9","article-title":"Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model","volume":"39","author":"F\u00e1varo","year":"2022","journal-title":"Med Oncol."},{"key":"10.1016\/j.tice.2022.101988_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejpb.2020.04.012","article-title":"Biogenic silver nanoparticles: In vitro and in vivo antitumor activity in bladder cancer","volume":"151","author":"Ferreira","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.tice.2022.101988_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s12885-016-2474-z","article-title":"Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier","volume":"16","author":"Garcia","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.tice.2022.101988_bib21","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.tice.2022.101988_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","article-title":"Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) Program","volume":"12","author":"Hayat","year":"2007","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.tice.2022.101988_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1196\/annals.1443.016","article-title":"RANK\/RANKL: Regulators of immune responses and bone physiology","volume":"1143","author":"Leibbrandt","year":"2008","journal-title":". N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.tice.2022.101988_bib24","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4049\/jimmunol.179.3.1568","article-title":"Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejection","volume":"179","author":"Li","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.tice.2022.101988_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2004.08.012","article-title":"Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression","volume":"6","author":"Luo","year":"2004","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.tice.2022.101988_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb07020.x","article-title":"Mechanism of action of camptothecin","volume":"922","author":"Liu","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.tice.2022.101988_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/14737140.2022.2046466","article-title":"Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer","volume":"22","author":"Lobo","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.tice.2022.101988_bib28","article-title":"Biomimetic Nanoerythrosome-Coated Aptamer-DNA Tetrahedron\/Maytansine Conjugates: pH-Responsive and Targeted Cytotoxicity for HER2-Positive Breast Cancer","volume":"22","author":"Ma","year":"2022","journal-title":"Adv. Mater."},{"issue":"2","key":"10.1016\/j.tice.2022.101988_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0165-1218(87)90016-4","article-title":"Guidelines for the conduct of micronucleus assays in mammalian bone marrow erythrocytes","volume":"189","author":"MacGregor","year":"1987","journal-title":"Mutat. Res."},{"issue":"20","key":"10.1016\/j.tice.2022.101988_bib30","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2010.03.007","article-title":"IFN-gamma-mediated up modulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer","volume":"28","author":"Martini","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.tice.2022.101988_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/BLC-179023","article-title":"Bladder sparing therapy for BCG failures - I - intravesical immunotherapy","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.tice.2022.101988_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbacli.2015.04.001","article-title":"Recent advances in the field of anti-cancer immunotherapy","volume":"3","author":"Neves","year":"2015","journal-title":"BBA Clin."},{"issue":"12","key":"10.1016\/j.tice.2022.101988_bib33","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/sj.bjc.6600615","article-title":"Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis","volume":"87","author":"Offersen","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tice.2022.101988_bib34","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.tice.2022.101988_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2022.101762","article-title":"OncoTherad\u00ae (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway","volume":"76","author":"Reis","year":"2022","journal-title":"Tissue Cell"},{"key":"10.1016\/j.tice.2022.101988_bib36","doi-asserted-by":"crossref","first-page":"01747","DOI":"10.1016\/j.tice.2022.101747","article-title":"Effects of combined OncoTherad immunotherapy and probiotic supplementation on modulating the chronic inflammatory process in colorectal carcinogenesis","volume":"75","author":"Reis","year":"2022","journal-title":"Tissue Cell"},{"key":"10.1016\/j.tice.2022.101988_bib37","first-page":"2022","article-title":"OncoTherad\u00ae is an immunomodulator of biological response that downregulate RANK\/RANKL signaling pathway and PD-1\/PD-L1 immune checkpoint in non-muscle invasive bladder cancer","author":"Reis","year":"2022","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tice.2022.101988_bib38","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160150","article-title":"RANK-RANKL signaling in cancer","volume":"36","author":"Renema","year":"2016","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.tice.2022.101988_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/tx500327y","article-title":"Use of cause-and-effect analysis to design a high-quality nanocytotoxicology assay","volume":"28","author":"R\u00f6sslein","year":"2015","journal-title":"Chem. Res. Toxicol."},{"issue":"6","key":"10.1016\/j.tice.2022.101988_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MCHD-0040-2016","article-title":"Toll-like receptor signaling and its inducible proteins","volume":"4","author":"Satoh","year":"2016","journal-title":"Microbiol. Spectr."},{"issue":"3","key":"10.1016\/j.tice.2022.101988_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutic","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6832","key":"10.1016\/j.tice.2022.101988_bib42","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.tice.2022.101988_bib43","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4049\/jimmunol.1101304","article-title":"Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells","volume":"188","author":"Shirota","year":"2012","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.tice.2022.101988_bib44","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"6812","key":"10.1016\/j.tice.2022.101988_bib45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/35046102","article-title":"T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-gamma","volume":"408","author":"Takayanagi","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tice.2022.101988_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2003.10.003","article-title":"TLR signaling pathways","volume":"16","author":"Takeda","year":"2004","journal-title":"Semin. Immunol."},{"issue":"8","key":"10.1016\/j.tice.2022.101988_bib47","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.7150\/ijbs.4694","article-title":"Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells","volume":"8","author":"Tate","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"14","key":"10.1016\/j.tice.2022.101988_bib48","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.tice.2022.101988_bib49","first-page":"244","article-title":"Bacillus-Calmette-Gu\u00e9rin non-responders: How to manage","volume":"4","author":"von Rundstedt","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.tice.2022.101988_bib50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.tice.2022.101988_bib51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrclinonc.2014.51","article-title":"Standing the test of time: targeting thymidylate biosynthesis in cancer therapy","volume":"11","author":"Wilson","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tice.2022.101988_bib52","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.tice.2022.101988_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2020.04.002","article-title":"Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy","volume":"223","author":"Yang","year":"2020","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.tice.2022.101988_bib54","article-title":"Facilitating in-situ tumor imaging with a tetrahedral DNA framework-enhanced hybridization chain reaction probe","volume":"32","author":"Zhang","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.tice.2022.101988_bib55","article-title":"Functionalizing framework nucleic-acid-based nanostructures for biomedical application","volume":"17","author":"Zhang","year":"2021","journal-title":"Adv. Mater."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816622002609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816622002609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:26:01Z","timestamp":1758572761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816622002609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":55,"alternative-id":["S0040816622002609"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2022.101988","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New synthetic nano-immunotherapy (OncoTherad\u00ae) for non-muscle invasive bladder cancer: Its synthesis, characterization and anticancer property","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2022.101988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101988"}}